Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Topics

Page Path

HOME
TOPICS
Topics

Letter to the Editor

Letter to the editor on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”

Weixiong Zhu, Xuefan Zeng, Zengxi Yang, Yusheng Cheng, Wence Zhou

Clin Mol Hepatol. 2025;31(3):e252-e253. Published online February 26, 2025

DOI: https://doi.org/10.3350/cmh.2025.0189

View: 1176 Download: 62

Research Letter

Mendelian randomization does not support the effects of G CSF on decompensated liver disease

Liling Li, Hui Wang, Hong Wang, Jinchang Huang

Clin Mol Hepatol. 2025;31(3):e254-e258. Published online March 4, 2025

DOI: https://doi.org/10.3350/cmh.2025.0172

View: 848 Download: 46

Lipidomic analysis of alcohol use disorder patients revealed the biomarkers for alcohol-related liver disease susceptibility

Dongyao Wang, Hongwei Zhang, Yuxiao Tang

Clin Mol Hepatol. 2025;31(3):e259-e262. Published online April 2, 2025

DOI: https://doi.org/10.3350/cmh.2025.0227

View: 831 Download: 67 Crossref: 1

Hydrophilic and lipophilic statin and clinical outcomes in individuals with alcohol-associated liver disease

Pojsakorn Danpanichkul, Donghee Kim, Benjamin Nah, Karn Wijarnpreecha, Suthat Liangpunsakul

Clin Mol Hepatol. 2025;31(3):e273-e276. Published online May 27, 2025

DOI: https://doi.org/10.3350/cmh.2025.0474

View: 530 Download: 20

Non-infectivity of hepatitis B virus under nucleoside analog therapy revealed through auxiliary partial orthotopic liver transplantation

Xiaojie Chen, Guiwen Guan, Lin Wei, Jidong Jia, Xiangmei Chen, Fengmin Lu, Zhijun Zhu

Clin Mol Hepatol. 2025;31(3):e263-e267. Published online May 8, 2025

DOI: https://doi.org/10.3350/cmh.2025.0393

View: 595 Download: 44

Contemporary burden of mortality from chronic liver disease by sex and race/ethnicity in the United States

Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed

Clin Mol Hepatol. 2025;31(3):e268-e272. Published online May 8, 2025

DOI: https://doi.org/10.3350/cmh.2025.0384

View: 595 Download: 36 Crossref: 1

Rising drug overdose deaths in chronic liver disease in the United States, 2015–2023

Donghee Kim, Brittany B Dennis, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed

Clin Mol Hepatol. 2025;31(3):e277-e280. Published online May 27, 2025

DOI: https://doi.org/10.3350/cmh.2025.0548

View: 523 Download: 24

Erratum

Erratum to ‘Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial’ [Clin Mol Hepatol 2024;30:807-823]

Sun Young Yim, Sung Hwan Lee, Seung-Woo Baek, Bohwa Sohn, Yun Seong Jeong, Sang-Hee Kang, Kena Park, Hyewon Park, Sunyoung S. Lee, Ahmed O. Kaseb, Young Nyun Park, Sun-Hee Leem, Michael A. Curran, Ji Hoon Kim, Ju-Seog Lee

Clin Mol Hepatol. 2025;31(2):669-670. Published online February 27, 2025

DOI: https://doi.org/10.3350/cmh.2024.0333e
Corrects: Clin Mol Hepatol 2024;30(4):807

View: 1221 Download: 46

Snapshot

Modulation of lymphatic vessels in management of liver disease and complications

Aarti Sharma, Pinky Juneja, Shiv K Sarin, Savneet Kaur

Clin Mol Hepatol. 2025;31(2):665-668. Published online October 17, 2024

DOI: https://doi.org/10.3350/cmh.2024.0793

View: 1339 Download: 67 Crossref: 1

Editorial

Screening of patients at high risk of de novo recurrence in HCC: Editorial on “Exploring methylation signatures for high de novo recurrence risk in hepatocellular carcinoma”

Ping Huang, Shiqiao Luo, Rui Liao

Clin Mol Hepatol. 2025;31(2):662-664. Published online February 11, 2025

DOI: https://doi.org/10.3350/cmh.2025.0106

View: 863 Download: 37

Metabolic dysfunction in patients following DAA-induced viral cure for HCV infection: A non-negligible risk to liver-related health: Editorial on “Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C”

Chen-Hua Liu, Yu-Ping Chang

Clin Mol Hepatol. 2025;31(2):658-661. Published online February 17, 2025

DOI: https://doi.org/10.3350/cmh.2025.0155

View: 1027 Download: 45 Web of Science: 2 Crossref: 2

Burden of alcohol use disorder, alcohol-related liver disease, and alcohol-related liver cancer: Editorial on “Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000–2021

Youxin Wang, Noriko Oza, Jazleen Leo, Ashok Choudhury, Daniel Q. Huang

Clin Mol Hepatol. 2025;31(2):654-657. Published online February 10, 2025

DOI: https://doi.org/10.3350/cmh.2025.0133

View: 1614 Download: 78 Web of Science: 1 Crossref: 1

Tetraspan(in)-mediated immune regulation in hepatocellular carcinoma: Editorial on “Targeting TM4SF1 promotes tumor senescence enhancing CD8⁺ T cell cytotoxic function in hepatocellular carcinoma”

Seo Hee Jin, Dong Joo Kim, Jung Weon Lee

Clin Mol Hepatol. 2025;31(2):650-653. Published online February 11, 2025

DOI: https://doi.org/10.3350/cmh.2025.0109

View: 1024 Download: 80

TM4SF1 - A new immune target for treatment of hepatocellular carcinoma: Editorial on “Targeting TM4SF1 promotes tumor senescence enhancing CD8+ T cell cytotoxic function in hepatocellular carcinoma”

Chen Rui Yuan, Terence Kin Wah Lee

Clin Mol Hepatol. 2025;31(2):646-649. Published online February 10, 2025

DOI: https://doi.org/10.3350/cmh.2025.0102

View: 1063 Download: 53

Targeting TM4SF1 to overcome immunotherapy resistance in hepatocellular carcinoma: Editorial on “Targeting TM4SF1 promotes tumor senescence enhancing CD8+ T cell cytotoxic function in hepatocellular carcinoma”

Valerie Chew

Clin Mol Hepatol. 2025;31(2):642-645. Published online January 16, 2025

DOI: https://doi.org/10.3350/cmh.2025.0031

View: 1107 Download: 51 Web of Science: 1 Crossref: 1

Is AMA M2 a useful serologic test for screening high-risk patients for PBC?: Editorial on “Prediction of primary biliary cholangitis among health check-up population with anti-mitochondrial M2 antibody positive”

Nae-Yun Heo

Clin Mol Hepatol. 2025;31(2):640-641. Published online February 13, 2025

DOI: https://doi.org/10.3350/cmh.2025.0117

View: 1253 Download: 35 Web of Science: 1 Crossref: 1

Genetic insights into sarcomatoid hepatocellular carcinoma: Critical role of ARID2 in pathogenesis and immune feature: Editorial on “Integrated molecular characterization of sarcomatoid hepatocellular carcinoma”

Naoshi Nishida

Clin Mol Hepatol. 2025;31(2):635-639. Published online January 24, 2025

DOI: https://doi.org/10.3350/cmh.2025.0071

View: 986 Download: 28 Web of Science: 1 Crossref: 1

Bridging the gap: The GOLM1-OPN-ABCG5 axis in MASH and gallstone disease: Editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”

Nahee Hwang, Sungsoon Fang

Clin Mol Hepatol. 2025;31(2):631-634. Published online February 3, 2025

DOI: https://doi.org/10.3350/cmh.2025.0066

View: 1304 Download: 49 Web of Science: 2 Crossref: 2

Unraveling the role of GOLM1-OPN-ABCG5 axis in MASH: Editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”

Yoon-su Ha, Won Kim, Seung-Jin Kim

Clin Mol Hepatol. 2025;31(2):628-630. Published online January 16, 2025

DOI: https://doi.org/10.3350/cmh.2025.0036

View: 1365 Download: 50 Web of Science: 2 Crossref: 2

Revealing the importance of a multidisciplinary approach to reducing the global burden of SLD through the COVID-19 pandemic: Editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023”

Jeayeon Park, Su Jong Yu

Clin Mol Hepatol. 2025;31(2):625-627. Published online January 16, 2025

DOI: https://doi.org/10.3350/cmh.2025.0019

View: 1095 Download: 20 Web of Science: 2 Crossref: 2

Vibration-controlled transient elastography in shaping the epidemiology and management of steatotic liver disease: Editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023”

Xiao-Dong Zhou, Terry Cheuk-Fung Yip, Daniel Q Huang, Mark Dhinesh Muthiah, Mazen Noureddin, Ming-Hua Zheng

Clin Mol Hepatol. 2025;31(2):620-624. Published online December 26, 2024

DOI: https://doi.org/10.3350/cmh.2024.1131

View: 1931 Download: 66 Web of Science: 2 Crossref: 3

Treating systemic inflammation by transjugular intrahepatic portosystemic shunt: Editorial on “Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis”

Georg Semmler, Lorenz Balcar, Mattias Mandorfer

Clin Mol Hepatol. 2025;31(2):615-619. Published online January 6, 2025

DOI: https://doi.org/10.3350/cmh.2024.1180

View: 1042 Download: 52 Web of Science: 3 Crossref: 2

A leap in the dark: Bariatric surgery for treatment of metabolic dysfunction-associated steatotic liver disease related cirrhosis: Editorial on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”

Jing Zeng, Jian-Gao Fan

Clin Mol Hepatol. 2025;31(2):610-614. Published online December 17, 2024

DOI: https://doi.org/10.3350/cmh.2024.1099

View: 1200 Download: 43 Web of Science: 2 Crossref: 2

Reconsidering treatment indications for chronic hepatitis B: Insights from the TORCH-B roll-over study: Editorial on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial”

Chih-Wen Wang, Ming-Lung Yu

Clin Mol Hepatol. 2025;31(2):606-609. Published online December 3, 2024

DOI: https://doi.org/10.3350/cmh.2024.1078

View: 1295 Download: 32 Web of Science: 1 Crossref: 1

Momentum towards simplifying and expanding treatment for chronic hepatitis B: The body of evidence continues to grow: Editorial on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial”

Robert J. Wong

Clin Mol Hepatol. 2025;31(2):603-605. Published online October 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.0929

View: 984 Download: 28 Web of Science: 1 Crossref: 1

Circulating cell-free mitochondrial DNA for diagnosing hepatocellular carcinoma and assessing prognosis: Editorial on “Aberrant fragmentomic features of circulating cell-free mitochondrial DNA enable early detection and prognosis prediction of hepatocellular carcinoma”

Hyuk soo Eun

Clin Mol Hepatol. 2025;31(2):599-602. Published online December 26, 2024

DOI: https://doi.org/10.3350/cmh.2024.1133

View: 1206 Download: 46 Crossref: 2

Universal self-testing as a cost-effective weapon to eliminate hepatitis C virus in the Republic of Korea: Editorial on “Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of disease burden and cost-effectiveness”

Eun Sun Jang

Clin Mol Hepatol. 2025;31(2):596-598. Published online November 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0992

View: 1072 Download: 23 Web of Science: 1 Crossref: 1

Stabilizing hepatic fatty acid oxidation: Editorial on “USP29 alleviates the progression of MASLD by stabilizing ACSL5 through K48 deubiquitination”

Myeung Gi Choi, Na Young Lee, Ja Hyun Koo

Clin Mol Hepatol. 2025;31(2):592-595. Published online November 6, 2024

DOI: https://doi.org/10.3350/cmh.2024.0971

View: 1791 Download: 93

Intrapatient variability of tacrolimus trough level may be not the cause, but an indirect parameter of comorbidities: Editorial on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”

Jongman Kim

Clin Mol Hepatol. 2025;31(2):589-591. Published online January 24, 2025

DOI: https://doi.org/10.3350/cmh.2025.0076

View: 997 Download: 40 Web of Science: 1 Crossref: 1

A novel clinical trial for primary sclerosing cholangitis from Asia: All regional endeavors should improve global management of primary sclerosing cholangitis: Editorial on “Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial”

Atsumasa Komori

Clin Mol Hepatol. 2025;31(2):584-588. Published online November 6, 2024

DOI: https://doi.org/10.3350/cmh.2024.0945

View: 1271 Download: 48 Web of Science: 1 Crossref: 1

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

Viewed By 13015	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7829	Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target
Viewed By 7333	MAFLD: How is it different from NAFLD?
Viewed By 5905	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 5842	Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment

Cited By 369	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 357	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 237	MAFLD: How is it different from NAFLD?
Cited By 122	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 118	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis